NeuroOne Reports 163% Revenue Growth to Record $9.1 Million Driven by Epilepsy Treatment Technology

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) reported preliminary unaudited product revenue growth of 163% to a record $9.1 million for the fiscal year ended September 30, 2025, compared to $3.5 million in fiscal 2024. The medical technology company also disclosed preliminary cash and cash equivalents of $6.6 million as of September 30, 2025. This substantial revenue increase represents one of the most significant growth trajectories in the neurological medical device sector and demonstrates accelerating market adoption of the company's innovative technologies.

Chief Executive Officer Dave Rosa attributed the impressive revenue growth to expanded customer interest and positive outcomes with the OneRF Ablation system for patients suffering from seizures associated with epilepsy. Rosa stated that the company believes it is well positioned to expand use of the OneRF technology platform, indicating potential for continued market penetration and technological applications. The OneRF system represents a significant advancement in minimally invasive treatment options for neurological disorders, potentially offering improved patient outcomes while reducing procedural costs.

The company will host a virtual investor webinar to discuss business operations and recent updates, featuring presentations from both CEO Dave Rosa and Chief Financial Officer Ron McClurg. The webinar will include a financial overview and discussion of recent milestone achievements, followed by a question-and-answer session. Investors can access the presentation through the NeuroOne website or via dial-in numbers provided in the announcement.

Complete financial results for the quarter are expected to be announced in December 2025. The company emphasized that the selected unaudited results are preliminary and subject to completion of accounting and interim review procedures, noting that prospective investors should exercise caution in relying on this information. This preliminary financial information should not be viewed as a substitute for full financial statements prepared in accordance with United States generally accepted accounting principles.

The implications of this revenue growth extend beyond NeuroOne's financial performance to the broader neurological treatment landscape. The 163% growth rate suggests strong market acceptance of the OneRF technology, which could signal a shift toward minimally invasive approaches for treating epilepsy and other neurological conditions. For patients suffering from treatment-resistant epilepsy, this technology represents potential new hope for seizure control without the risks associated with traditional brain surgery. The medical community may view these results as validation of the technology's clinical utility, potentially accelerating adoption across more treatment centers.

For the medical device industry, NeuroOne's performance demonstrates the commercial viability of specialized neurological technologies and may encourage increased investment in similar innovative treatments. The company's focus on improving surgical care options and outcomes for patients suffering from neurological disorders addresses a significant unmet medical need, with potential applications extending to Parkinson's disease, dystonia, essential tremors, and chronic pain conditions. The substantial revenue growth during a single fiscal year indicates that healthcare providers are increasingly recognizing the value of advanced neurological technologies that can improve patient outcomes while potentially reducing overall healthcare costs.